Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inhibitor questions: plasma-derived factor VIII and recombinant factor VIII.

× No keyword cloud information.

14 in total

Review 1. Current status of clinical studies of recombinant factor VIII (recombinate) in patients with hemophilia A. Recombinate Study Group.

Authors: G L Bray
Journal: Transfus Med Rev Date: 1992-10

2. Hemophilia, a clinical study of 40 patients.

Authors: C S DAVIDSON; R D EPSTEIN
Journal: Blood Date: 1949-02 Impact factor: 22.113

3. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates.

Authors: I Schwarzinger; I Pabinger; C Korninger; F Haschke; M Kundi; H Niessner; K Lechner
Journal: Am J Hematol Date: 1987-03 Impact factor: 10.047

4. Jaundice and antibodies directed against factors 8 and 9 in patients treated for haemophilia or Christmas disease in the United Kingdom.

Authors: R Biggs
Journal: Br J Haematol Date: 1974-03 Impact factor: 6.998

5. The natural history of factor VIII inhibitors in patients with hemophilia A.

Authors: F M Gill
Journal: Prog Clin Biol Res Date: 1984

6. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.

Authors: J E Addiego; E Gomperts; S L Liu; P Bailey; S G Courter; M L Lee; G G Neslund; H S Kingdon; M J Griffith
Journal: Thromb Haemost Date: 1992-01-23 Impact factor: 5.249

7. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome.

Authors: V Rasi; E Ikkala
Journal: Br J Haematol Date: 1990-11 Impact factor: 6.998

8. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.

Authors: K Peerlinck; J Arnout; J G Gilles; J M Saint-Remy; J Vermylen
Journal: Thromb Haemost Date: 1993-02-01 Impact factor: 5.249

9. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.

Authors: S Ehrenforth; W Kreuz; I Scharrer; R Linde; M Funk; T Güngör; B Krackhardt; B Kornhuber
Journal: Lancet Date: 1992-03-07 Impact factor: 79.321

10. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.

Authors: J M Lusher; S Arkin; C F Abildgaard; R S Schwartz
Journal: N Engl J Med Date: 1993-02-18 Impact factor: 91.245

1 in total

1. Product type and other environmental risk factors for inhibitor development in severe hemophilia A.

Authors: Flora Peyvandi; Isabella Garagiola
Journal: Res Pract Thromb Haemost Date: 2018-04-10

1 in total